Non-small cell lung cancer (NSCLC)

• Phase II trial of amivantamab plus monochemotherapy in platinum unfit NSCLC patients with EGFR exon20 insertion mutations Pending
  2025-520676-26-00 4
• Hyperprogression upon cemiplimab alone or with chemotherapy in PD-L1 ≥ 50% NSCLC: a biomarker guided phase 2 trial – HYPERBOLIC study Pending
  2025-521583-35-00 4
• DB-1311 in Combination with BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors Pending
  2025-523895-22-00 4
• A clinical study of MK-1084 with other treatments for non-small cell lung cancer (MK-3475-01F) Recruiting
  2024-512248-47-00 9 2026-04-15
• Phase II study on the safety and feasibility of stool transplants in limited non-small cell lung cancer patients, using donors who responded … Recruiting
  2025-521251-24-00 4 2025-12-01
• A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III N … Recruiting
  2023-503920-14-00 5 2024-01-02
• Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies Recruiting
  2024-513033-21-00 3 2020-09-14
• Study of STK-012 Alone and with Other Treatments in Patients with Advanced Lung Cancer and Other Cancers Recruiting
  2025-522632-14-00 4 2026-05-11
• A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Program … Recruiting
  2025-521281-97-00 5 2025-12-02
• Study of the treatment of patients with non-small cell lung cancer with metastasis with Cemiplimab and subsequent treatment with Cemiplimab … Recruiting
  2024-518812-38-00 4 2025-07-02
• Phase II clinical trial of chemotherapy + atezolizumab for stage IIIa and IIIb non-small cell lung cancer followed by atezolizumab as adjuva … Recruiting
  2024-515984-68-00 4 2025-05-20
• A clinical study of MK-2870 and chemotherapy to treat lung cancer (MK-2870-009) Recruiting
  2023-504910-31-00 5 2024-07-15
• Neoadjuvant Immunotherapy with Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) foll … Recruiting
  2024-518804-32-00 9 2021-02-16
• MK-2870 versus Chemotherapy in Previously Treated or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other … Recruitment ended
  2023-503539-16-00 5 2025-11-11
• A Study of Subcutaneous Nivolumab plus Intravenous Ipilimumab and Chemotherapy in Participants with Previously Untreated Metastatic or Recur … Recruitment ended
  2024-520108-25-00 4 2025-11-05
• DART (19-14434) Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study inves … Recruitment ended
  2022-502640-12-01 9 2024-09-27
• Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736). An open label randomized phase II trial with durvalumab following Stereotacti … Recruitment ended
  2024-512439-54-01 4 2024-07-24
• A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either … Recruitment ended
  2023-503357-35-00 4 2024-03-20
• A study of sigvotatug vedotin versus docetaxel in previously treated non-small cell lung cancer (Be6A Lung-01) Recruitment ended
  2023-503827-25-01 5 2024-02-16
• eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients Recruitment ended
  2024-513454-29-00 5 2015-10-15
• The NeoTRACK Trial – Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – Dissection of IO efficacy in NSCLC by longitudinal tracKing: a … Halted
  2022-501322-38-00 4 2023-05-26
• A Phase 2 Study of PRT3789 in Combination with Pembrolizumab in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation Ended
  2024-516889-11-00 4 2025-05-21
• Study of Repotrectinib and CYP450 probe Cocktail in Patients with locally advanced or Metastatic Tyrosine Kinase Inhibitors (TKI)-Pretreated … Ended
  2024-511030-12-00 3 2025-02-03
• A clinical study for patients with newly diagnosed, locally advanced non-small cell lung cancer (NSCLC) with a change in the ALK-gene, to te … Ended
  2022-502467-38-00 4 2024-02-22

Showing 1–24 of 34 trials